Detection of serum hMAM and CD147 levels of patients with breast cancer and its clinical significance
10.13481/j.1671-587x.20180627
- Author:
Xiuyan YU
1
Author Information
1. Department of Clinical Laboratory, Tumor Hospital
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Extracellular matrix metalloproteinase inducer;
Human mammaglobin;
Sensitivity;
Specificity
- From:
Journal of Jilin University(Medicine Edition)
2018;44(6):1269-1274
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the serum levels and the positive expression rates of human mammaglobin (hMAM) and extracellular matrix metalloproteinase inducer (CD147) of the patients with breast cancer, and to clarify their clinical significnaces in the diagnosis of breast cancer. Methods: A total of 122 patients with breast cancer (breast cancer group), 21 patients with breast fibroadenoma (breast fibroadenoma group) and 16 healthy controls (healthy control group) were selected as the subjects. The serum samples of subjects in various groups were collected. The serum levels and the positive expression rates of hMAM and CD147 of the subjects in various groups were measured by ELISA method. The serum levels and the positive expression rates of hMAM and CD147 of the breast cancer patients with different clinicopathological features were analyzed. The cut-off values of serum levels of hMAM and CD147 of the patients with breast cancer and their sensitivities and specificities in the dignosis of breast cancer were comfirmed by receiver operating characteristic (ROC) curve. Results: The serum levels of hMAM and CD147 of the patients in breast cancer group were higher than those in healthy control group and breast fibroadenoma group (P<0. 05). The positive expression rates of hMAM and CD147 of the patients in breast cancer group were higher than those in healthy control group and breast fibroadenoma group (P<0. 01); while the positive expression rates of serum hMAM combined with CD147 of the patients in breast cancer group were higher than those in healthy control group and breast fibroadenoma group (P<0. 01). There were significant differences in the positive expression rates of serum hMAM and CD147 of breast cancer patients with lymph node metastasis or not (χ2=10. 375, P<0. 01; χ2=15. 556, P<0. 01). There were significant differences in the positive expression rates of serum CD147 of the breast cancer patients with different TNM stages, ER and Her-2 (χ2= 8157, P<0.05; χ2= 6. 035, P<0. 05;χ2 = 5. 385, P<0. 05). With the increasing of TNM stages, the positive expression rates of serum hMAM and CD147 were increased. The area under ROC curve (AUC) of serum level of hMAM was 0. 809, 95%CI; 0.703-0.916; the AUC of serum level of CD147 was 0. 721, 95% Cl: 0.582-0.861. When the cut-off value of hMAM was 6. 51 μg · L-1, its sensitivity and specificity were 61. 1% and 87. 5%, respectively. The sensitivity and specificity were 73.6% and 68.7% respectively when the cut-off value of CD147 was 144. 92 ng · L-1. The AUC of detection of hMAM combined with CD147 was 0. 880, 95% Cl: 0. 798-0. 962; the sensitivity and specificity were 80. 6% and 81. 2%, respectively. Conclusion; The serum level of hMAM has the high sensitivity and specificity in the diagnosis of breast cancer. Combined detection of hMAM and CD147 can improve the positive rate of diagnosis.
